株探米国株
日本語 英語
エドガーで原本を確認する
false 0001142750 0001142750 2025-05-08 2025-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 8, 2025

 

AMN HEALTHCARE SERVICES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware 001-16753 06-1500476
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
     

2999 Olympus Boulevard, Suite 500

Dallas, Texas 75019

(Address of principal executive offices) (Zip Code)
 
(866) 871-8519
(Registrant’s Telephone Number, Including Area Code)
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act  (17 CFR 240.14d-2(b))
     
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act  (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbol(s)  

Name of each exchange

on which registered

Common Stock, par value $0.01 per share   AMN   NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

     

Item 2.02. Results of Operations and Financial Condition.

On May 8, 2025, AMN Healthcare Services, Inc. reported its results for the fiscal quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.   Description
   
99.1   Press Release issued on May 8, 2025
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

     

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AMN Healthcare Services, Inc.  
       
       

Date: May 8, 2025

By: /s/ Cary Grace  
  Name:

Cary Grace

 
  Title:  Chief Executive Officer  

 

 

 

 

     

EX-99.1 2 eh250625026_ex9901.htm EXHIBIT 99.1

EXHIBIT 99.1 

 

 

AMN HEALTHCARE ANNOUNCES FIRST QUARTER 2025 RESULTS

 

Quarterly revenue of $690 million;

 

GAAP loss of ($0.03)/share and adjusted EPS of $0.45

 

DALLAS — AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2025 financial results. Financial highlights are as follows:

 

Dollars in millions, except per share amounts.

    Q1 2025   % Change Q1 2024
Revenue   $ 689.5       (16 %)
Gross profit   $ 198.1       (23 %)
Net loss   $ (1.1 )     nm  
Diluted loss per share   $ (0.03 )     nm  
Adjusted diluted EPS*   $ 0.45       (54 %)
Adjusted EBITDA*   $ 64.2       (34 %)

 

* See “Non-GAAP Measures” below for a discussion of our use of non-GAAP items and the table entitled “Non-GAAP Reconciliation Tables” for a reconciliation of non-GAAP items.

 

Business Highlights

First quarter revenue and earnings were above the high end of guidance, with labor disruption, locum tenens and allied revenue better than expected and other businesses coming in line.
Consolidated gross margin was better than guidance, and effective SG&A management delivered operating leverage.
Improved bookings driven by technology and process improvements grew locum tenens revenue sequentially, and the business is trending to return to year-over-year revenue growth.
Modern Healthcare named AMN in its 2025 Innovators Awards, recognizing our WorkWise workforce technology suite and AMN Passport mobile career platform.
Cash flow from operations was strong at $93 million in the first quarter, which allowed us to reduce debt by $60 million. Our net leverage ratio at quarter end was 3.1:1.

 

  1  

“Our financial results for the first three months of 2025 yielded positive upside in revenue and operating leverage. We are benefiting from growth in our clients' patient volumes, continued normalization in our industry, and market adoption of our tech-enabled talent solutions,” said Cary Grace, President and Chief Executive Officer of AMN Healthcare. “Clients remain cost-conscious and are monitoring possible impacts from tariffs and healthcare regulatory and legislative proposals. We continue to be confident in our opportunity to gain market share and increase revenue over time through our diversified suite of healthcare workforce solutions.”

 

 

First Quarter 2025 Results

Consolidated revenue for the quarter was $690 million, a 16% decrease from prior year and a 6% decrease from the prior quarter. Net loss was $1 million (0.2% of revenue), or ($0.03) per diluted share, compared with net income of $17 million (2.1% of revenue), or $0.45 per diluted share, in the first quarter of 2024. Adjusted diluted EPS in the first quarter was $0.45 compared with $0.97 in the same quarter a year ago.

 

Revenue for the Nurse and Allied Solutions segment was $413 million, lower by 20% year over year and down 9% from the prior quarter. Travel nurse staffing revenue was lower by 36% year over year and 6% sequentially. Allied division revenue declined 13% year over year and was 1% lower than the prior quarter. Labor disruption events contributed $39 million revenue in the quarter.

 

The Physician and Leadership Solutions segment reported revenue of $174 million, down 8% year over year but up 1% sequentially. Locum tenens revenue was $141 million, 3% lower year over year but 3% higher sequentially. Interim leadership revenue was down by 21% year over year and 9% lower sequentially. Our physician and leadership search businesses saw revenue decline by 29% year over year and 8% quarter over quarter.

 

Technology and Workforce Solutions segment revenue was $102 million, a decrease of 9% year over year and 4% sequentially. Language services revenue was $75 million in the

 

  2  

quarter, 5% higher than the prior year and down 2% sequentially. Vendor management systems revenue was $19 million, 33% lower year over year and down 14% from the prior quarter.

 

Consolidated gross margin was 28.7%, 270 basis points lower year over year and down 110 basis points sequentially. Gross margin declined year over year and sequentially across all three of our business segments, offset in part by a revenue mix shift toward higher-margin segments.

 

Consolidated SG&A expenses were $148 million, or 21.4% of revenue, compared with $175 million, or 21.3% of revenue, in the same quarter last year. SG&A was $159 million, or 21.6% of revenue, in the previous quarter. The year-over-year decrease in SG&A costs was driven primarily by lower employee, professional services, and bad debt expenses.

 

Income from operations was $13 million with an operating margin of 1.8%, compared with $40 million and 4.9%, respectively, in the same quarter last year. Adjusted EBITDA was $64 million, a year-over-year decrease of 34%. Adjusted EBITDA margin was 9.3%, 260 basis points lower than the year-ago period.

 

At March 31, 2025, cash and cash equivalents totaled $56 million. Cash flow from operations was $93 million for the first quarter. Capital expenditures were $10 million. The Company ended the quarter with total debt outstanding of $1.0 billion.

 

 

  3  

Second Quarter 2025 Outlook

 

Metric   Guidance*
Consolidated revenue   $645 - $660 million
Gross margin   28.5% - 29.0%
SG&A as percentage of revenue   23.2% - 23.7%
Operating margin   (0.7%) - 0.0%
Adjusted EBITDA margin   7.8% - 8.3%

*Note: Guidance percentage metrics are approximate. For a reconciliation of adjusted EBITDA margin, see the table entitled “Reconciliation of Guidance Operating Margin to Guidance Adjusted EBITDA Margin” below.

 

Revenue in the second quarter of 2025 is expected to be 11-13% lower than the prior year and down 4-7% sequentially. Nurse and Allied Solutions segment revenue is expected to be down 14-17% year over year. Physician and Leadership Solutions segment revenue is expected to be 5-7% lower year over year. Technology and Workforce Solutions segment revenue is projected to be lower by 8-10% year over year. Guidance includes $16 million in labor disruption revenue.

 

Second quarter estimates for certain other financial items include depreciation of $19 million, depreciation in cost of revenue of $2 million, non-cash amortization expense of $20 million, share-based compensation expense of $11 million, integration and other expenses of $3 million, interest expense of $11.5 million, an adjusted tax rate of 28%, and 38.6 million diluted average shares outstanding.

 

 

  4  

 

Conference Call on May 8, 2025

AMN Healthcare Services, Inc. (NYSE: AMN) will host a conference call to discuss its first quarter 2025 financial results and second quarter 2025 outlook on Thursday, May 8, 2025 at 5:00 p.m. Eastern Time. A live webcast of the call can be accessed through AMN Healthcare’s website at http://ir.amnhealthcare.com. Interested parties may participate live via telephone by registering at this link. Registrants will receive confirmation and dial-in details. Following the conclusion of the call, a replay of the webcast will be available at the Company’s investor relations website.

 

About AMN Healthcare

AMN Healthcare is the leader and innovator in total talent solutions for healthcare organizations across the nation. The Company provides access to the most comprehensive network of quality healthcare professionals through its innovative recruitment strategies and breadth of career opportunities. With insights and expertise, AMN Healthcare helps providers optimize their workforce to successfully reduce complexity, increase efficiency and improve patient outcomes. AMN total talent solutions include direct staffing, vendor-neutral and managed services programs, clinical and interim healthcare leaders, temporary staffing, permanent placement, executive search, vendor management systems, recruitment process outsourcing, predictive modeling, language services, revenue cycle solutions, and other services. Our diverse client base includes acute-care hospitals, community health centers and clinics, physician practice groups, retail and urgent care centers, home health facilities, schools, inpatient/outpatient rehabilitation facilities, ambulatory care facilities, outpatient surgical facilities, and many other healthcare settings.

 

The Company’s common stock is listed on the New York Stock Exchange under the symbol “AMN.” For more information about AMN Healthcare, visit www.amnhealthcare.com, where the Company posts news releases, investor presentations, webcasts, SEC filings and other material information. The Company also utilizes email alerts and Really Simple Syndication (“RSS”) as routine channels to supplement distribution of this information. To register for email alerts and RSS, visit http://ir.amnhealthcare.com.

 

  5  

 

Non-GAAP Measures

This earnings release and the non-GAAP reconciliation tables included with the earnings release contain certain non-GAAP financial information, which the Company provides as additional information, and not as an alternative, to the Company’s condensed consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures include (1) adjusted EBITDA, (2) adjusted EBITDA margin, (3) adjusted net income, and (4) adjusted diluted EPS. The Company provides such non-GAAP financial measures because management believes that they are useful to both management and investors as a supplement, and not as a substitute, when evaluating the Company’s operating performance. Additionally, management believes that adjusted EBITDA, adjusted EBITDA margin, and adjusted diluted EPS serve as industry-wide financial measures. The Company uses adjusted EBITDA for making financial decisions, allocating resources and for determining certain incentive compensation objectives. The non-GAAP measures in this release are not in accordance with, or an alternative to, GAAP measures and may be different from non-GAAP measures, or may be calculated differently than other similarly titled non-GAAP measures, reported by other companies. They should not be used in isolation to evaluate the Company’s performance. A reconciliation of non-GAAP measures identified in this release, along with further detail about the use and limitations of certain of these non-GAAP measures, may be found below in the table entitled “Non-GAAP Reconciliation Tables” under the caption entitled “Reconciliation of Non-GAAP Items” and the footnotes thereto or on the Company’s website at https://ir.amnhealthcare.com/financials/quarterly-results. Additionally, from time to time, additional information regarding non-GAAP financial measures, including pro forma measures, may be made available on the Company’s website.

 

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning future demand and supply for healthcare, contingent staffing and other services, market adoption of our tech-enabled solutions, ability to gain market share or increase revenue through our diversified workforce solutions, our ability to produce year-over-year revenue growth in the second quarter 2025, second quarter 2025 financial projections for consolidated and segment revenue, consolidated gross margin, operating margin, SG&A as a percent of revenue, adjusted EBITDA margin, labor disruption revenue, depreciation expense, depreciation in cost of revenue, non-cash amortization expense, share-based compensation expense, integration and other expenses, interest expense, adjusted tax rate, and number of diluted shares outstanding. The Company bases these forward-looking statements on its current expectations, estimates and

 

  6  

 

projections about future events and the industry in which it operates using information currently available to it. Actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are also identified by words such as “believe,” "project," “anticipate,” “expect,” “intend,” “plan,” “will,” “may,” “estimates,” variations of such words and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

 

The targets and expectations noted in this release depend upon, among other factors, (i) the ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts, through predictive analytics, online recruiting, internal travel agencies and float pools, telemedicine or otherwise and successfully hire and retain permanent staff, (ii) the duration and extent to which hospitals and other healthcare entities adjust their utilization of temporary nurses and allied healthcare professionals, physicians, healthcare leaders and other healthcare professionals and workforce technology applications as a result of the labor market or economic conditions, (iii) the magnitude and duration of the effects of the post-COVID-19 pandemic environment or any future pandemic or health crisis on demand and supply trends, our business, its financial condition and our results of operations, (iv) our ability to effectively address client demand by attracting and placing nurses and other clinicians, (v) our ability to recruit and retain sufficient quality healthcare professionals at reasonable costs, (vi) our ability to anticipate and quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, or client needs and requirements, including implementing changes that will make our services more tech-enabled and integrated, (vii) our ability to manage the pricing impact that the labor market or consolidation of healthcare delivery organizations may have on our business, (viii) the effects of economic downturns, inflation or slow recoveries, which could result in less demand for our services, increased client initiatives designed to contain costs, including reevaluating their approach as it pertains to contingent labor and managed services programs, other solutions and providers, pricing pressures and negatively impact payments terms and collectability of accounts receivable, (ix) our ability to develop and evolve our current technology offerings and capabilities and implement new infrastructure and technology systems to optimize our operating results and manage our business effectively, (x) our ability and the expense to comply with extensive and complex federal and state laws and regulations related to the conduct of our operations, costs and payment for services and payment for referrals as well as laws regarding employment practices, (xi) our ability to consummate and effectively incorporate acquisitions into our business, (xii) the negative effects that intermediary organizations may have on our ability to secure new and profitable contracts, (xiii) the extent to which the Great Resignation or a future spike in the COVID-19 pandemic or other pandemic or health crisis may disrupt our operations due to the unavailability of our employees or healthcare

 

  7  

professionals due to burnout, illness, risk of illness, quarantines, travel restrictions, mandatory vaccination requirements, or other factors that limit our existing or potential workforce and pool of candidates, (xiv) security breaches and cybersecurity incidents, including ransomware, that could compromise our information and systems, which could adversely affect our business operations and reputation and could subject us to substantial liabilities and (xv) the severity and duration of the impact the labor market, economic downturn or any future pandemic or health crisis has on the financial condition and cash flow of many hospitals and healthcare systems such that it impairs their ability to make payments to us, timely or otherwise, for services rendered.

 

For a discussion of additional risk factors and a more complete discussion of some of the cautionary statements noted above that could cause actual results to differ from those implied by the forward-looking statements contained in this press release, please refer to our most recent Annual Report on Form 10-K for the year ended December 31, 2024. Be advised that developments subsequent to this press release are likely to cause these statements to become outdated and the Company is under no obligation (and expressly disclaims any such obligation) to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

 

 

Contact:

Randle Reece

Vice President, Investor Relations & Strategy

866.861.3229

 

 

 

  8  

 

AMN Healthcare Services, Inc.

Condensed Consolidated Statements of Comprehensive Income (Loss)

(in thousands, except per share amounts)

(unaudited)

 

 

    Three Months Ended
    March 31,   December 31,
    2025   2024   2024
Revenue   $ 689,533     $ 820,878     $ 734,709  
Cost of revenue     491,413       563,372       515,721  
Gross profit     198,120       257,506       218,988  
Gross margin     28.7 %     31.4 %     29.8 %
Operating expenses:                        
Selling, general and administrative (SG&A)     147,731       174,842       158,922  
SG&A as a % of revenue     21.4 %     21.3 %     21.6 %
                         
Depreciation and amortization (exclusive of depreciation included in cost of revenue)     37,882       42,719       40,161  
Goodwill impairment losses     —         —         222,457  
Total operating expenses     185,613       217,561       421,540  
Income (loss) from operations     12,507       39,945       (202,552 )
Operating margin (1)     1.8 %     4.9 %     (27.6 )%
                         
Interest expense, net, and other (2)     12,324       16,628       23,114  
                         
Income (loss) before income taxes     183       23,317       (225,666 )
                         
Income tax expense (benefit)     1,275       5,989       (38,133 )
Net income (loss)   $ (1,092 )   $ 17,328     $ (187,533 )
Net income (loss) as a % of revenue     (0.2 )%     2.1 %     (25.5 )%
                         
Other comprehensive income:                        
Unrealized gains on available-for-sale securities, net, and other     61       84       45  
Other comprehensive income     61       84       45  
                         
Comprehensive income (loss)   $ (1,031 )   $ 17,412     $ (187,488 )
                         
Net income (loss) per common share:                        
Basic   $ (0.03 )   $ 0.45     $ (4.90 )
Diluted   $ (0.03 )   $ 0.45     $ (4.90 )
Weighted average common shares outstanding:                        
Basic     38,312       38,114       38,263  
Diluted     38,312       38,197       38,263  

 

 

  9  

 

AMN Healthcare Services, Inc.

Condensed Consolidated Balance Sheets

(dollars in thousands)

(unaudited)

 

 

   

March 31,

2025

  December 31, 2024  

March 31,

2024

Assets                        
Current assets:                        
Cash and cash equivalents   $ 55,777     $ 10,649     $ 50,560  
Accounts receivable, net     421,869       437,817       578,647  
Accounts receivable, subcontractor     65,307       70,481       97,516  
Prepaid and other current assets     84,404       75,968       64,023  
Total current assets     627,357       594,915       790,746  
Restricted cash, cash equivalents and investments     45,070       71,840       71,912  
Fixed assets, net     177,996       186,270       194,537  
Other assets     253,670       258,053       252,397  
Deferred income taxes, net     31,637       25,829       —    
Goodwill     897,456       897,456       1,114,757  
Intangible assets, net     361,937       381,364       449,248  
Total assets   $ 2,395,123     $ 2,415,727     $ 2,873,597  
                         
Liabilities and stockholders’ equity                        
Current liabilities:                        
Accounts payable and accrued expenses   $ 195,974     $ 184,311     $ 316,016  
Accrued compensation and benefits     269,497       287,544       280,513  
Other current liabilities     116,778       73,930       27,374  
Total current liabilities     582,249       545,785       623,903  
Revolving credit facility     150,000       210,000       425,000  
Notes payable, net     846,167       845,872       844,984  
Deferred income taxes, net     —         —         15,472  
Other long-term liabilities     101,656       107,450       110,047  
Total liabilities     1,680,072       1,709,107       2,019,406  
                         
Commitments and contingencies                        
                         
Stockholders’ equity:     715,051       706,620       854,191  
                         
Total liabilities and stockholders’ equity   $ 2,395,123     $ 2,415,727     $ 2,873,597  
                         

 

  10  

 

AMN Healthcare Services, Inc.

Summary Condensed Consolidated Statements of Cash Flows

(dollars in thousands)

(unaudited)

 

 

    Three Months Ended
    March 31,   December 31,
    2025   2024   2024
             
Net cash provided by operating activities   $ 92,671     $ 81,386     $ 72,814  
Net cash used in investing activities     (26,046 )     (21,399 )     (14,203 )
Net cash used in financing activities     (61,211 )     (38,973 )     (79,898 )
Net increase (decrease) in cash, cash equivalents and restricted cash     5,414       21,014       (21,287 )
Cash, cash equivalents and restricted cash at beginning of period     89,305       108,273       110,592  
Cash, cash equivalents and restricted cash at end of period   $ 94,719     $ 129,287     $ 89,305  

 

 

 

 

  11  

 

AMN Healthcare Services, Inc.

Non-GAAP Reconciliation Tables

(dollars in thousands, except per share data)

(unaudited)

 

 

    Three Months Ended
    March 31,   December 31,
    2025   2024   2024
Reconciliation of Non-GAAP Items:            
             
Net income (loss)   $ (1,092 )   $ 17,328     $ (187,533 )
Income tax expense (benefit)     1,275       5,989       (38,133 )
Income (loss) before income taxes     183       23,317       (225,666 )
Interest expense, net, and other (2)     12,324       16,628       23,114  
Income (loss) from operations     12,507       39,945       (202,552 )
Depreciation and amortization     37,882       42,719       40,161  
Depreciation (included in cost of revenue) (3)     1,975       1,798       1,313  
Goodwill impairment losses     —         —         222,457  
Share-based compensation     9,381       7,739       3,666  
Acquisition, integration, and other costs (4)     2,455       5,465       10,078  
Adjusted EBITDA (5)   $ 64,200     $ 97,666     $ 75,123  
                         
Adjusted EBITDA margin (6)     9.3 %     11.9 %     10.2 %
                         
Net income (loss)   $ (1,092 )   $ 17,328     $ (187,533 )
Adjustments:                        
Amortization of intangible assets     19,427       24,886       21,036  
Acquisition, integration, and other costs (4)     2,455       5,465       10,078  
Goodwill impairment losses     —         —         222,457  
Fair value changes of equity investments and instruments (2)     —         —         9,730  
Tax effect on above adjustments     (5,689 )     (7,891 )     (47,100 )
Tax effect of COLI fair value changes (7)     703       (2,734 )     (290 )
Tax deficiencies (benefits) related to equity awards and ESPP (8)     1,523       174       465  
Adjusted net income (9)   $ 17,327     $ 37,228     $ 28,843  
                         
GAAP diluted net income (loss) per share (EPS)   $ (0.03 )   $ 0.45     $ (4.90 )
Adjustments     0.48       0.52       5.65  
Adjusted diluted EPS (10) (11)   $ 0.45     $ 0.97     $ 0.75  

 

 

  12  

 

AMN Healthcare Services, Inc.

Supplemental Segment Financial and Operating Data

(dollars in thousands, except operating data)

(unaudited)

 

 

    Three Months Ended
    March 31,   December 31,
    2025   2024   2024
Revenue            
Nurse and allied solutions   $ 413,261     $ 519,297     $ 454,654  
Physician and leadership solutions     174,065       188,797       173,141  
Technology and workforce solutions     102,207       112,784       106,914  
    $ 689,533     $ 820,878     $ 734,709  
                         
Segment operating income (12)                        
Nurse and allied solutions   $ 32,238     $ 53,342     $ 38,932  
Physician and leadership solutions     14,462       22,222       17,032  
Technology and workforce solutions     35,250       44,270       40,278  
      81,950       119,834       96,242  
Unallocated corporate overhead (13)     17,750       22,168       21,119  
Adjusted EBITDA (5)   $ 64,200     $ 97,666     $ 75,123  
                         
Gross Margin                        
Nurse and allied solutions     22.7 %     25.1 %     23.8 %
Physician and leadership solutions     27.3 %     31.6 %     28.5 %
Technology and workforce solutions     55.5 %     59.9 %     57.3 %
                         
Operating Data:                        
Nurse and allied solutions                        
Average travelers on assignment (14)     8,981       11,524       9,206  
                         
Physician and leadership solutions                        
Days filled (15)     51,342       56,849       51,641  
Revenue per day filled (16)   $ 2,743     $ 2,555     $ 2,646  
                         

 

    As of March 31,   As of December 31,
    2025   2024   2024
Leverage ratio (17)     3.1       2.4       3.0  
                         

 

  13  

 

AMN Healthcare Services, Inc.

Additional Supplemental Non-GAAP Disclosure

Reconciliation of Guidance Operating Margin to Guidance

Adjusted EBITDA Margin

(unaudited)

 

 

    Three Months Ended
    June 30, 2025
      Low(18)       High(18)  
                 
Operating margin     (0.7 )%     0.0 %
Depreciation and amortization (total)     6.3 %     6.2 %
EBITDA margin     5.6 %     6.2 %
Share-based compensation     1.6 %     1.6 %
Integration and other costs     0.5 %     0.5 %
Adjusted EBITDA margin     7.8 %     8.3 %

 

 

  14  

 

(1) Operating margin represents income (loss) from operations divided by revenue.
(2) Changes in the fair value of equity investments and instruments are recognized in interest expense, net, and other. Since the changes in fair value are unrelated to the Company’s operating performance, we exclude the impact from the calculation of adjusted net income and adjusted diluted EPS.
(3) A portion of depreciation expense for AMN Language Services is included in cost of revenue. We exclude the impact of depreciation included in cost of revenue from the calculation of adjusted EBITDA.
(4) Acquisition, integration, and other costs include acquisition and integration costs, net changes in the fair value of contingent consideration liabilities for recently acquired companies, certain legal expenses, restructuring expenses and other costs associated with exit or disposal activities, and certain nonrecurring expenses, which we exclude from the calculation of adjusted EBITDA, adjusted net income, and adjusted diluted EPS because we believe that these expenses are not indicative of the Company’s operating performance. For the three months ended March 31, 2025, acquisition and integration costs were approximately $0.3 million, expenses related to the closures of certain office leases were approximately $0.2 million, certain legal expenses were approximately $1.1 million, restructuring expenses and other costs associated with exit or disposal activities were approximately $0.4 million, and other nonrecurring expenses were approximately $0.4 million. For the three months ended March 31, 2024, acquisition and integration costs were approximately $0.8 million, expenses related to the closures of certain office leases were approximately $0.5 million, certain legal expenses were approximately $1.2 million, restructuring expenses and other costs associated with exit or disposal activities were approximately $1.0 million, and other nonrecurring expenses were approximately $2.0 million. For the three months ended December 31, 2024, acquisition and integration costs were approximately $0.4 million, expenses related to the closures of certain office leases were approximately $0.5 million, restructuring expenses and other costs associated with exit or disposal activities were approximately $0.4 million, and other expenses were approximately $8.8 million. Included in other expenses was an immaterial out-of-period adjustment of $7.3 million related to a revenue-based state tax audit.
(5) Adjusted EBITDA represents net income (loss) plus interest expense (net of interest income) and other, income tax expense (benefit), depreciation and amortization, depreciation (included in cost of revenue), goodwill impairment losses, share-based compensation, acquisition, integration, and other costs, restructuring expenses, and certain legal expenses. Management believes that adjusted EBITDA provides an effective measure of the Company’s results, as it excludes certain items that management believes are not indicative of the Company’s operating performance. Adjusted EBITDA is not intended to represent cash flows for the period, nor has it been presented as an alternative to income (loss) from operations or net income (loss) as an indicator of operating performance. Although management believes that some of the items excluded from adjusted EBITDA are not indicative of the Company’s operating performance, these items do impact the statement of comprehensive income (loss), and management therefore utilizes adjusted EBITDA as an operating performance measure in conjunction with GAAP measures such as net income (loss).
(6) Adjusted EBITDA margin represents adjusted EBITDA divided by revenue.
(7) The Company records net tax expense (benefit) related to the income tax treatment of the fair value changes in the cash surrender value of its company owned life insurance. Since this change in fair value is unrelated to the Company’s operating performance, we excluded the impact on adjusted net income and adjusted diluted EPS.
(8) The consolidated effective tax rate is affected by the recording of tax benefits and tax deficiencies related to equity awards vested during the period and tax benefits recognized for disqualifying dispositions related to our employee stock purchase plan (“ESPP”). The magnitude of the impact of tax benefits and tax deficiencies generated in the future related to equity awards and ESPP is dependent upon the Company’s future grants of share-based compensation, the Company’s future stock price on the date equity awards vest in relation to the fair value of the awards on the grant date, the Company’s future stock price on either the ESPP’s offering date or purchase date, whichever is lower, and the length of time the shares issued under the ESPP are held by employees. Since these tax benefits and tax deficiencies related to equity awards and ESPP are largely unrelated to our income (loss) before taxes and are unrepresentative of our normal effective tax rate, we excluded their impact in the calculation of adjusted net income and adjusted diluted EPS.
(9) Adjusted net income represents GAAP net income (loss) excluding the impact of the (A) amortization of intangible assets, (B) acquisition, integration, and other costs, (C) goodwill impairment losses, (D) certain legal expenses, (E) changes in fair value of equity investments and instruments, (F) deferred financing related costs, (G) tax effect, if any, of the foregoing adjustments, (H) net tax expense (benefit) related to the income tax treatment of fair value changes in the cash surrender value of its company owned life insurance, (I) tax benefits and tax deficiencies related to equity awards vested and ESPP, and (J) restructuring tax benefits. Management

 

  15  

 

included this non-GAAP measure to provide investors and prospective investors with an alternative method for assessing the Company’s operating results in a manner that is focused on its operating performance and to provide a more consistent basis for comparison between periods. However, investors and prospective investors should note that this non-GAAP measure involves judgment by management (in particular, judgment as to what is classified as a special item to be excluded in the calculation of adjusted net income). Although management believes the items in the calculation of adjusted net income are not indicative of the Company’s operating performance, these items do impact the statement of comprehensive income (loss), and management therefore utilizes adjusted net income as an operating performance measure in conjunction with GAAP measures such as GAAP net income (loss).

(10) Adjusted diluted EPS represents adjusted net income divided by diluted weighted average common shares outstanding. Management included this non-GAAP measure to provide investors and prospective investors with an alternative method for assessing the Company’s operating results in a manner that is focused on its operating performance and to provide a more consistent basis for comparison between periods. However, investors and prospective investors should note that this non-GAAP measure involves judgment by management (in particular, judgment as to what is classified as a special item to be excluded in the calculation of adjusted net income). Although management believes the items in the calculation of adjusted net income are not indicative of the Company’s operating performance, these items do impact the statement of comprehensive income (loss), and management therefore utilizes adjusted diluted EPS as an operating performance measure in conjunction with GAAP measures such as GAAP diluted EPS.
(11) As GAAP net loss is reported for the three months ended March 31, 2025 and December, 31, 2024, basic weighted average common shares outstanding was used to calculate GAAP diluted EPS for both periods because the dilutive potential common shares have an anti-dilutive effect (i.e., result in a lower loss per share). As adjusted net income is reported for the three months ended March 31, 2025 and December 31, 2024, diluted weighted average common shares outstanding (including dilutive potential common shares) of 38,414 and 38,329, respectively, were used to calculate adjusted diluted EPS.
(12) Segment operating income represents net income (loss) plus interest expense (net of interest income) and other, income tax expense (benefit), depreciation and amortization, depreciation (included in cost of revenue), unallocated corporate overhead, acquisition, integration, and other costs, legal settlement accrual changes, share-based compensation and goodwill impairment losses.
(13) Unallocated corporate overhead (as presented in the tables above) consists of unallocated corporate overhead (as reflected in our quarterly and annual financial statements filed with the SEC) less acquisition, integration, and other costs and legal settlement accrual changes.
(14) Average travelers on assignment represents the average number of nurse and allied healthcare professionals on assignment during the period presented.
(15) Days filled is calculated by dividing the locum tenens hours filled during the period by eight hours.
(16) Revenue per day filled represents revenue of the Company’s locum tenens business divided by days filled for the period presented.
(17) Leverage ratio represents the ratio of the consolidated funded indebtedness (as calculated per the Company’s credit agreement) at the end of the subject period to the consolidated adjusted EBITDA (as calculated per the Company’s credit agreement) for the twelve-month period ended at the end of the subject period.
(18) Guidance percentage metrics are approximate.

 

  16